Positive Minds Strong Bodies Implementation (PMSB-E)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04545593 |
Recruitment Status :
Recruiting
First Posted : September 11, 2020
Last Update Posted : April 5, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Depression Anxiety Physical Disability | Behavioral: Positive Minds Strong Bodies Enhanced Behavioral: Enhanced Usual Care | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 450 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Masking Description: | Research staff conducting follow up assessments will be blinded to participant condition in the trial. |
Primary Purpose: | Treatment |
Official Title: | Building Community Capacity for Disability Prevention for Minority Elders - Renewal |
Actual Study Start Date : | February 11, 2021 |
Estimated Primary Completion Date : | September 30, 2024 |
Estimated Study Completion Date : | September 30, 2024 |

Arm | Intervention/treatment |
---|---|
Experimental: Positive Minds Strong Bodies Enhanced
The Positive Minds Strong Bodies Enhanced intervention (PMSB-E) consists of 10 sessions focused on mental health (PM) and 36 sessions focused on physical health (SB), along with a group maintenance component.
|
Behavioral: Positive Minds Strong Bodies Enhanced
The Positive Minds Strong Bodies Enhanced intervention (PMSB-E) was designed to provide a single, integrated program that could address the dual challenges of mental health and disability among minority elders. PMSB-E seeks to improve mood symptoms, identify and correct negative distortions or cognitions, promote behavioral activation through engaging the participant in pleasant activities, and encourage developing supportive relationships. All sessions are tailored to the participant's needs using a collaborative approach. |
Active Comparator: Enhanced Usual Care
The Enhanced Usual Care condition includes written materials on depression and anxiety and 4 calls to participants over the course of 6 months to assess symptoms and safety.
|
Behavioral: Enhanced Usual Care
Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. Research staff will call the participant 4 times over the course of 6 months to administer mental health items, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group. |
- Acceptability [ Time Frame: 6 months at end of treatment ]>/= 70% of participants attending >/= 50% of their intervention sessions, reporting satisfaction with treatment.
- Hopkins Symptom Checklist-25 (change) [ Time Frame: Baseline and 3, 6, and 12 months after baseline ]Widely used measure of depression and anxiety in clinical monitoring and outcome assessment.
- Short Physical Performance Battery (change) [ Time Frame: Baseline and 3, 6, and 12 months after baseline ]Assessment of standing balance, timed 4-m walk, and timed test of five chair-rise repetitions, to assess functional limitations. A virtual option will be used while in person assessment is not possible due to COVID-19.
- Late-Life Function and Disability Instrument (LLFDI) - functional component (change) [ Time Frame: Baseline and 3, 6, and 12 months after baseline ]Self-report instrument designed to measure both functional capacity and components of disability.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 60 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Latino, Asian, Black, or non-Latino White adults 60+ years of age
- With mild, moderate or severe depressive or anxiety symptoms.
- Participants receiving medications for mental health will have this recorded and used as a covariate.
- Community-dwelling participants who have some mobility limitations but are not home-bound.
Exclusion Criteria:
- Any specialty mental health care (therapy sessions with psychiatrist, psychologist or social worker) in the past 3 months or scheduled in the coming month.
- Evidence that patient lacks capacity to consent or is cognitively impaired
- Current suicidal risk (score of 4 or 5 on Paykel suicide questionnaire), whereby participant will be connected to an emergency services or specialty provider per the study emergency protocol.
- Physically instability, acute or exacerbation of a chronic disease, or a neuro-musculoskeletal impairment
- Severe substance abuse
- Self-reported psychosis or schizophrenia
- Inability to commit to 2 sessions per week

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04545593
Contact: Margarita Alegria, Ph.D. | (617) 724-4987 | malegria@mgh.harvard.edu | |
Contact: Sheri Markle, MIA | 617-643-5042 | smarkle@mgh.harvard.edu |
United States, Massachusetts | |
Massachusetts General Hospital | Recruiting |
Boston, Massachusetts, United States, 02114 | |
Contact: Margarita Alegria, PhD 617-724-4987 malegria@mgh.harvard.edu | |
Contact: Sheri L Markle, MIA 617-643-5042 smarkle@mgh.harvard.edu |
Responsible Party: | Margarita Alegria, PhD, Chief, Disparities Research Unit, Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT04545593 |
Other Study ID Numbers: |
2019P001292 |
First Posted: | September 11, 2020 Key Record Dates |
Last Update Posted: | April 5, 2022 |
Last Verified: | April 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Minority Elders |
Depression Behavioral Symptoms |